Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-kappaB signaling.
Identifieur interne : 001785 ( PubMed/Checkpoint ); précédent : 001784; suivant : 001786Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-kappaB signaling.
Auteurs : Matthew Frieman [États-Unis] ; Kiira Ratia ; Robert E. Johnston ; Andrew D. Mesecar ; Ralph S. BaricSource :
- Journal of virology [ 1098-5514 ] ; 2009.
Descripteurs français
- KwdFr :
- Cysteine endopeptidases (métabolisme), Facteur de transcription NF-kappa B (métabolisme), Facteur-3 de régulation d'interféron (métabolisme), Humains, Inhibiteur alpha de NF-KappaB, Interférons (antagonistes et inhibiteurs), Lignée cellulaire, Phosphorylation, Protéines I-kappa B (métabolisme), Protéines virales (métabolisme), Virus du SRAS (enzymologie).
- MESH :
- antagonistes et inhibiteurs : Interférons.
- enzymologie : Virus du SRAS.
- métabolisme : Cysteine endopeptidases, Facteur de transcription NF-kappa B, Facteur-3 de régulation d'interféron, Protéines I-kappa B, Protéines virales.
- Humains, Inhibiteur alpha de NF-KappaB, Lignée cellulaire, Phosphorylation.
English descriptors
- KwdEn :
- MESH :
- chemical , antagonists & inhibitors : Interferons.
- chemical , metabolism : Cysteine Endopeptidases, I-kappa B Proteins, Interferon Regulatory Factor-3, NF-kappa B, Viral Proteins.
- enzymology : SARS Virus.
- Cell Line, Humans, NF-KappaB Inhibitor alpha, Phosphorylation.
Abstract
The outcome of a viral infection is regulated in part by the complex coordination of viral and host interactions that compete for the control and optimization of virus replication. Severe acute respiratory syndrome coronavirus (SARS-CoV) intimately engages and regulates the host innate immune responses during infection. Using a novel interferon (IFN) antagonism screen, we show that the SARS-CoV proteome contains several replicase, structural, and accessory proteins that antagonize the IFN pathway. In this study, we focus on the SARS-CoV papain-like protease (PLP), which engages and antagonizes the IFN induction and NF-kappaB signaling pathways. PLP blocks these pathways by affecting activation of the important signaling proteins in each pathway, IRF3 and NF-kappaB. We also show that the ubiquitin-like domain of PLP is necessary for pathway antagonism but not sufficient by itself to block these pathways regardless of the enzymatic activity of the protease. The potential mechanism of PLP antagonism and its role in pathogenesis are discussed.
DOI: 10.1128/JVI.02220-08
PubMed: 19369340
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:19369340Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-kappaB signaling.</title><author><name sortKey="Frieman, Matthew" sort="Frieman, Matthew" uniqKey="Frieman M" first="Matthew" last="Frieman">Matthew Frieman</name><affiliation wicri:level="1"><nlm:affiliation>Department of Epidemiology, University of North Carolina, Chapel Hill, North Carolina 27599, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Epidemiology, University of North Carolina, Chapel Hill, North Carolina 27599</wicri:regionArea><wicri:noRegion>North Carolina 27599</wicri:noRegion></affiliation></author><author><name sortKey="Ratia, Kiira" sort="Ratia, Kiira" uniqKey="Ratia K" first="Kiira" last="Ratia">Kiira Ratia</name></author><author><name sortKey="Johnston, Robert E" sort="Johnston, Robert E" uniqKey="Johnston R" first="Robert E" last="Johnston">Robert E. Johnston</name></author><author><name sortKey="Mesecar, Andrew D" sort="Mesecar, Andrew D" uniqKey="Mesecar A" first="Andrew D" last="Mesecar">Andrew D. Mesecar</name></author><author><name sortKey="Baric, Ralph S" sort="Baric, Ralph S" uniqKey="Baric R" first="Ralph S" last="Baric">Ralph S. Baric</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="RBID">pubmed:19369340</idno><idno type="pmid">19369340</idno><idno type="doi">10.1128/JVI.02220-08</idno><idno type="wicri:Area/PubMed/Corpus">001927</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001927</idno><idno type="wicri:Area/PubMed/Curation">001927</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001927</idno><idno type="wicri:Area/PubMed/Checkpoint">001785</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001785</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-kappaB signaling.</title><author><name sortKey="Frieman, Matthew" sort="Frieman, Matthew" uniqKey="Frieman M" first="Matthew" last="Frieman">Matthew Frieman</name><affiliation wicri:level="1"><nlm:affiliation>Department of Epidemiology, University of North Carolina, Chapel Hill, North Carolina 27599, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Epidemiology, University of North Carolina, Chapel Hill, North Carolina 27599</wicri:regionArea><wicri:noRegion>North Carolina 27599</wicri:noRegion></affiliation></author><author><name sortKey="Ratia, Kiira" sort="Ratia, Kiira" uniqKey="Ratia K" first="Kiira" last="Ratia">Kiira Ratia</name></author><author><name sortKey="Johnston, Robert E" sort="Johnston, Robert E" uniqKey="Johnston R" first="Robert E" last="Johnston">Robert E. Johnston</name></author><author><name sortKey="Mesecar, Andrew D" sort="Mesecar, Andrew D" uniqKey="Mesecar A" first="Andrew D" last="Mesecar">Andrew D. Mesecar</name></author><author><name sortKey="Baric, Ralph S" sort="Baric, Ralph S" uniqKey="Baric R" first="Ralph S" last="Baric">Ralph S. Baric</name></author></analytic><series><title level="j">Journal of virology</title><idno type="eISSN">1098-5514</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cell Line</term><term>Cysteine Endopeptidases (metabolism)</term><term>Humans</term><term>I-kappa B Proteins (metabolism)</term><term>Interferon Regulatory Factor-3 (metabolism)</term><term>Interferons (antagonists & inhibitors)</term><term>NF-KappaB Inhibitor alpha</term><term>NF-kappa B (metabolism)</term><term>Phosphorylation</term><term>SARS Virus (enzymology)</term><term>Viral Proteins (metabolism)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Cysteine endopeptidases (métabolisme)</term><term>Facteur de transcription NF-kappa B (métabolisme)</term><term>Facteur-3 de régulation d'interféron (métabolisme)</term><term>Humains</term><term>Inhibiteur alpha de NF-KappaB</term><term>Interférons (antagonistes et inhibiteurs)</term><term>Lignée cellulaire</term><term>Phosphorylation</term><term>Protéines I-kappa B (métabolisme)</term><term>Protéines virales (métabolisme)</term><term>Virus du SRAS (enzymologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Interferons</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Cysteine Endopeptidases</term><term>I-kappa B Proteins</term><term>Interferon Regulatory Factor-3</term><term>NF-kappa B</term><term>Viral Proteins</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Interférons</term></keywords><keywords scheme="MESH" qualifier="enzymologie" xml:lang="fr"><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="enzymology" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Cysteine endopeptidases</term><term>Facteur de transcription NF-kappa B</term><term>Facteur-3 de régulation d'interféron</term><term>Protéines I-kappa B</term><term>Protéines virales</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Cell Line</term><term>Humans</term><term>NF-KappaB Inhibitor alpha</term><term>Phosphorylation</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Inhibiteur alpha de NF-KappaB</term><term>Lignée cellulaire</term><term>Phosphorylation</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The outcome of a viral infection is regulated in part by the complex coordination of viral and host interactions that compete for the control and optimization of virus replication. Severe acute respiratory syndrome coronavirus (SARS-CoV) intimately engages and regulates the host innate immune responses during infection. Using a novel interferon (IFN) antagonism screen, we show that the SARS-CoV proteome contains several replicase, structural, and accessory proteins that antagonize the IFN pathway. In this study, we focus on the SARS-CoV papain-like protease (PLP), which engages and antagonizes the IFN induction and NF-kappaB signaling pathways. PLP blocks these pathways by affecting activation of the important signaling proteins in each pathway, IRF3 and NF-kappaB. We also show that the ubiquitin-like domain of PLP is necessary for pathway antagonism but not sufficient by itself to block these pathways regardless of the enzymatic activity of the protease. The potential mechanism of PLP antagonism and its role in pathogenesis are discussed.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19369340</PMID><DateCompleted><Year>2009</Year><Month>06</Month><Day>18</Day></DateCompleted><DateRevised><Year>2020</Year><Month>03</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-5514</ISSN><JournalIssue CitedMedium="Internet"><Volume>83</Volume><Issue>13</Issue><PubDate><Year>2009</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Journal of virology</Title><ISOAbbreviation>J. Virol.</ISOAbbreviation></Journal><ArticleTitle>Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-kappaB signaling.</ArticleTitle><Pagination><MedlinePgn>6689-705</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.02220-08</ELocationID><Abstract><AbstractText>The outcome of a viral infection is regulated in part by the complex coordination of viral and host interactions that compete for the control and optimization of virus replication. Severe acute respiratory syndrome coronavirus (SARS-CoV) intimately engages and regulates the host innate immune responses during infection. Using a novel interferon (IFN) antagonism screen, we show that the SARS-CoV proteome contains several replicase, structural, and accessory proteins that antagonize the IFN pathway. In this study, we focus on the SARS-CoV papain-like protease (PLP), which engages and antagonizes the IFN induction and NF-kappaB signaling pathways. PLP blocks these pathways by affecting activation of the important signaling proteins in each pathway, IRF3 and NF-kappaB. We also show that the ubiquitin-like domain of PLP is necessary for pathway antagonism but not sufficient by itself to block these pathways regardless of the enzymatic activity of the protease. The potential mechanism of PLP antagonism and its role in pathogenesis are discussed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Frieman</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, University of North Carolina, Chapel Hill, North Carolina 27599, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ratia</LastName><ForeName>Kiira</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Johnston</LastName><ForeName>Robert E</ForeName><Initials>RE</Initials></Author><Author ValidYN="Y"><LastName>Mesecar</LastName><ForeName>Andrew D</ForeName><Initials>AD</Initials></Author><Author ValidYN="Y"><LastName>Baric</LastName><ForeName>Ralph S</ForeName><Initials>RS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>F32 AI066542</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AI059443</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01AI060915</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32AI066542</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01AI059443</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AI060915</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>04</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Virol</MedlineTA><NlmUniqueID>0113724</NlmUniqueID><ISSNLinking>0022-538X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020672">I-kappa B Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C494232">IRF3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050838">Interferon Regulatory Factor-3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606204">NFKBIA protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>139874-52-5</RegistryNumber><NameOfSubstance UI="D000072000">NF-KappaB Inhibitor alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>9008-11-1</RegistryNumber><NameOfSubstance UI="D007372">Interferons</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="C099456">3C-like proteinase, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D003546">Cysteine Endopeptidases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003546" MajorTopicYN="N">Cysteine Endopeptidases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020672" MajorTopicYN="N">I-kappa B Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050838" MajorTopicYN="N">Interferon Regulatory Factor-3</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007372" MajorTopicYN="N">Interferons</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072000" MajorTopicYN="N">NF-KappaB Inhibitor alpha</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016328" MajorTopicYN="N">NF-kappa B</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014764" MajorTopicYN="N">Viral Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>4</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>4</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>6</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19369340</ArticleId><ArticleId IdType="pii">JVI.02220-08</ArticleId><ArticleId IdType="doi">10.1128/JVI.02220-08</ArticleId><ArticleId IdType="pmc">PMC2698564</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Virol. 2000 Jan;74(1):371-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10590126</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2005 Sep 9;122(5):645-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16143094</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2000 Nov;74(22):10623-30</Citation><ArticleIdList><ArticleId IdType="pubmed">11044106</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):12289-94</Citation><ArticleIdList><ArticleId IdType="pubmed">11027311</ArticleId></ArticleIdList></Reference><Reference><Citation>Cytokine Growth Factor Rev. 2001 Jun-Sep;12(2-3):143-56</Citation><ArticleIdList><ArticleId IdType="pubmed">11325598</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2001 May 10;283(2):230-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11336548</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Microbiol Rev. 2001 Oct;14(4):778-809, table of contents</Citation><ArticleIdList><ArticleId IdType="pubmed">11585785</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2002 May;76(10):5251-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11967338</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2003 Jan;77(2):1501-11</Citation><ArticleIdList><ArticleId IdType="pubmed">12502864</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunol Lett. 2003 Jan 22;85(2):85-95</Citation><ArticleIdList><ArticleId IdType="pubmed">12527213</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Immunol. 2003 May;4(5):491-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12692549</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1967-76</Citation><ArticleIdList><ArticleId IdType="pubmed">12690091</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1953-66</Citation><ArticleIdList><ArticleId IdType="pubmed">12690092</ArticleId></ArticleIdList></Reference><Reference><Citation>J Tradit Chin Med. 2003 Sep;23(3):214-7</Citation><ArticleIdList><ArticleId IdType="pubmed">14535196</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12995-3000</Citation><ArticleIdList><ArticleId IdType="pubmed">14569023</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15889-94</Citation><ArticleIdList><ArticleId IdType="pubmed">14673108</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2004 Jan 17;363(9404):234-6</Citation><ArticleIdList><ArticleId IdType="pubmed">14738798</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann N Y Acad Sci. 2003 Dec;1010:237-48</Citation><ArticleIdList><ArticleId IdType="pubmed">15033728</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2004 Aug;78(15):7863-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15254158</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2004 Oct 29;279(44):45528-39</Citation><ArticleIdList><ArticleId IdType="pubmed">15319427</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 1994 Apr;68(4):2433-41</Citation><ArticleIdList><ArticleId IdType="pubmed">8139028</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 1995 May 19;81(4):551-60</Citation><ArticleIdList><ArticleId IdType="pubmed">7758109</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1996 Jul 15;157(2):815-21</Citation><ArticleIdList><ArticleId IdType="pubmed">8752933</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 1997 Apr 14;230(2):217-27</Citation><ArticleIdList><ArticleId IdType="pubmed">9143277</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):14040-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16169905</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2005 Nov;79(21):13399-411</Citation><ArticleIdList><ArticleId IdType="pubmed">16227261</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2005 Oct 20;437(7062):1167-72</Citation><ArticleIdList><ArticleId IdType="pubmed">16177806</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2005 Dec;79(24):15189-98</Citation><ArticleIdList><ArticleId IdType="pubmed">16306590</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2006 Mar;80(6):3009-20</Citation><ArticleIdList><ArticleId IdType="pubmed">16501110</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5717-22</Citation><ArticleIdList><ArticleId IdType="pubmed">16581910</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2006 Jun;80(11):5156-67</Citation><ArticleIdList><ArticleId IdType="pubmed">16698996</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2006 Jun;80(11):5644-50</Citation><ArticleIdList><ArticleId IdType="pubmed">16699046</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2006 Jul;80(13):6637-47</Citation><ArticleIdList><ArticleId IdType="pubmed">16775351</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Exp Med Biol. 2006;581:37-41</Citation><ArticleIdList><ArticleId IdType="pubmed">17037501</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2007 Jan;81(1):237-47</Citation><ArticleIdList><ArticleId IdType="pubmed">17079324</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2007 Jan;81(2):548-57</Citation><ArticleIdList><ArticleId IdType="pubmed">17108024</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2007 Feb 1;109(3):1131-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16985170</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2007 Mar;81(6):2554-63</Citation><ArticleIdList><ArticleId IdType="pubmed">17182678</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO J. 2007 Jul 25;26(14):3451-62</Citation><ArticleIdList><ArticleId IdType="pubmed">17599067</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2007 Sep;81(18):9812-24</Citation><ArticleIdList><ArticleId IdType="pubmed">17596301</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Pathog. 2007 Aug 10;3(8):e112</Citation><ArticleIdList><ArticleId IdType="pubmed">17696609</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2007 Nov;81(21):11620-33</Citation><ArticleIdList><ArticleId IdType="pubmed">17715225</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Soc Trans. 2007 Nov;35(Pt 5):942-5</Citation><ArticleIdList><ArticleId IdType="pubmed">17956251</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2007 Nov 2;282(44):32208-21</Citation><ArticleIdList><ArticleId IdType="pubmed">17761676</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2007 Nov;81(22):12135-44</Citation><ArticleIdList><ArticleId IdType="pubmed">17804504</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2008 May;82(9):4471-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18305050</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2008 May;82(10):4920-30</Citation><ArticleIdList><ArticleId IdType="pubmed">18353963</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Res. 2008 Nov;18(11):1105-13</Citation><ArticleIdList><ArticleId IdType="pubmed">18957937</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 1997 Dec 22;239(2):389-401</Citation><ArticleIdList><ArticleId IdType="pubmed">9434729</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 1998 Apr 10;243(2):406-14</Citation><ArticleIdList><ArticleId IdType="pubmed">9568039</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 1998 Dec 20;252(2):324-30</Citation><ArticleIdList><ArticleId IdType="pubmed">9878611</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2004 Nov;4(11):704-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15522683</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2004 Dec;78(24):13600-12</Citation><ArticleIdList><ArticleId IdType="pubmed">15564471</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17264-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15563593</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2005 Feb;79(4):2001-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15681402</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Immunol. 2005;23:307-36</Citation><ArticleIdList><ArticleId IdType="pubmed">15771573</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Immunol. 2005 Jul;26(7):396-401</Citation><ArticleIdList><ArticleId IdType="pubmed">15922665</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Immunol. 2005 Jun;35(6):1918-27</Citation><ArticleIdList><ArticleId IdType="pubmed">15884053</ArticleId></ArticleIdList></Reference><Reference><Citation>J Interferon Cytokine Res. 2000 Feb;20(2):205-15</Citation><ArticleIdList><ArticleId IdType="pubmed">10714557</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country></list><tree><noCountry><name sortKey="Baric, Ralph S" sort="Baric, Ralph S" uniqKey="Baric R" first="Ralph S" last="Baric">Ralph S. Baric</name><name sortKey="Johnston, Robert E" sort="Johnston, Robert E" uniqKey="Johnston R" first="Robert E" last="Johnston">Robert E. Johnston</name><name sortKey="Mesecar, Andrew D" sort="Mesecar, Andrew D" uniqKey="Mesecar A" first="Andrew D" last="Mesecar">Andrew D. Mesecar</name><name sortKey="Ratia, Kiira" sort="Ratia, Kiira" uniqKey="Ratia K" first="Kiira" last="Ratia">Kiira Ratia</name></noCountry><country name="États-Unis"><noRegion><name sortKey="Frieman, Matthew" sort="Frieman, Matthew" uniqKey="Frieman M" first="Matthew" last="Frieman">Matthew Frieman</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001785 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001785 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:19369340
|texte= Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-kappaB signaling.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:19369340" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |